title: Is preclinical data sharing the new norm?
abstract: Is preclinical data sharing the new norm? In my experience, it is certainly becoming more commonplace. However, it is not yet standard practice and remains the preserve of special projects. Here, I expound the benefits of sharing proprietary preclinical data using examples of successful initiatives. The main barriers to data sharing are then described, with suggestions for how these might be overcome. To maximise the benefits and minimise the risks involved, I suggest that organisations look to develop standard operating procedures for data sharing.
authors.affiliation: Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds LS11 5PS, UK. Electronic address: Katharine.briggs@lhasalimited.org.
authors.forename: Katharine A
authors.initials: KA
authors.lastname: Briggs
mesh_terms: D000818:Animals; D004353:Drug Evaluation, Preclinical / Q000592:standards; D006801:Humans; D033181:Information Dissemination / Q000379:methods*